This article is a correction to:
MSC therapy ameliorates experimental gouty arthritis hinting an early COX-2 induction
Juan Pablo Medina1†
Ismael Bermejo-Álvarez1†
Sandra Pérez-Baos1
Rosa Yáñez2,3
María Fernández-García2,3
Damián García-Olmo4,5,6
Aránzazu Mediero1
Gabriel Herrero-Beaumont1*
Raquel Largo1- 1Bone and Joint Research Unit, Rheumatology Dept, IIS-Fundación Jiménez Díaz Universidad Autonoma de Madrid (UAM), Madrid, Spain
- 2Hematopoietic Innovative Therapies Division, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT) and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBER-ER), Madrid, Spain
- 3Advanced Therapies Dept, IIS-Fundación Jiménez Díaz UAM, Madrid, Spain
- 4New Therapies Laboratory, IIS-Fundación Jiménez Díaz UAM, Madrid, Spain
- 5Department of Surgery, Fundación Jiménez Díaz University Hospital, Madrid, Spain
- 6Department of Surgery, School of Medicine UAM, Madrid, Spain
A Corrigendum on
MSC therapy ameliorates experimental gouty arthritis hinting an early COX-2 induction
by Medina JP, Bermejo-Álvarez I, Pérez-Baos S, Yáñez R, Fernández-García M, García-Olmo D, Mediero A, Herrero-Beaumont G and Largo R (2023). Front. Immunol. 14:1193179. doi: 10.3389/fimmu.2023.1193179
In the published article, there was an error in the Funding statement. The funding statement was displayed as “This study was supported by research grants from the Instituto de Salud Carlos III (PIE15/00048; PI15/00770; PI18/00261; PI20/00349; PI22/00352), co-funded by Fondo Europeo de Desarrollo Regional (FEDER).” The correct statement is “This study was supported by research grants from the Instituto de Salud Carlos III (PIE15/00048; PI15/00770; PI18/00261; PI20/00349; PI22/00352), co-funded by the European Union.”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: mesenchymal stem cells (MSCs), innate inflammation, macrophage, polarization, inflammasome, prostaglandin E2, COX-2
Citation: Medina JP, Bermejo-Álvarez I, Pérez-Baos S, Yáñez R, Fernández-García M, García-Olmo D, Mediero A, Herrero-Beaumont G and Largo R (2023) Corrigendum: MSC therapy ameliorates experimental gouty arthritis hinting an early COX-2 induction. Front. Immunol. 14:1345777. doi: 10.3389/fimmu.2023.1345777
Received: 28 November 2023; Accepted: 29 November 2023;
Published: 06 December 2023.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2023 Medina, Bermejo-Álvarez, Pérez-Baos, Yáñez, Fernández-García, García-Olmo, Mediero, Herrero-Beaumont and Largo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Gabriel Herrero-Beaumont, gherrero@fjd.es
†These authors have contributed equally to this work and share first authorship